Central nervous system toxicity of metallic nanoparticles

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 4321-4340

  Feng, Xiaoli ^a   Chen, Aijie ^a   Zhang, Yanli ^a   Wang, Jianfeng ^b   Shao, Longquan ^a   Wei, Limin ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Autophagy; Blood brain barrier; Nanomaterials; Neurotoxicity; ROS

Indexed keywords

CARBON NANOTUBE; DRUG CARRIER; MULTI WALLED NANOTUBE; NANOPARTICLE; METAL NANOPARTICLE;

ALZHEIMER DISEASE; APOPTOSIS; BLOOD BRAIN BARRIER; BRAIN TUMOR; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG TARGETING; HEALTH HAZARD; HUMAN; HUNTINGTON CHOREA; IMMUNE RESPONSE; MICROELECTROMECHANICAL SYSTEM; MOLECULAR IMAGING; NERVE CELL; NERVE REGENERATION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PARKINSON DISEASE; PARTICLE SIZE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SURFACE PROPERTY; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS;

CENTRAL NERVOUS SYSTEM; HUMANS; METAL NANOPARTICLES;

EID: 84936887301     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S78308     Document Type: Review

References (174)

1. Buzea C, Pacheco Blandino II, Robbie K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases. 2007;2(4):17–71.
2. Bleeker EAJ, de Jong WH, Geertsma RE, et al. Considerations on the EU definition of a nanomaterial: science to support policy making. Regul Toxicol Pharmacol. 2013;65(1):119–125.
3. Kettiger H, Schipanski A, Wick P, Huwyler J. Engineered nanomaterial uptake and tissue distribution: from cell to organism. Int J Nanomedicine. 2013;8:3255–3269.
4. Kao YY, Cheng TJ, Yang DM, Wang CT, Chiung YM, Liu PS. Demonstration of an olfactory bulb-brain translocation pathway for ZnO nanoparticles in rodent cells in vitro and in vivo. J Mol Neurosci. 2012;48(2):464–471.
5. Wiley DT, Webster P, Gale A, Davis ME. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci U S A. 2013;110(21):8662–8667.
6. Raghnaill MN, Bramini M, Ye D, et al. Paracrine signalling of inflammatory cytokines from an in vitro blood brain barrier model upon exposure to polymeric nanoparticles. Analyst. 2014;139(5):923–930.
7. Wu J, Ding TT, Sun J. Neurotoxic potential of iron oxide nanoparticles in the rat brain striatum and hippocampus. Neurotoxicology. 2013;34: 243–253.
8. Han DD, Tian YT, Zhang T, Ren GG, Yang Z. Nano-zinc oxide damages spatial cognition capability via over-enhanced long-term potentiation in hippocampus of Wistar rats. Int J Nanomedicine. 2011;6:1453–1461.
9. Chen JY, Dong X, Xin YY, Zhao MR. Effects of titanium dioxide nano-particles on growth and some histological parameters of zebrafish (Danio rerio) after a long-term exposure. Aquat Toxicol. 2011;101(3–4):493–499.
10. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, RadomskiMW. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol. 2007;150(5):552–558.
11. Hu RP, Zheng L, Zhang T, et al. Molecular mechanism of hippocampal apoptosis of mice following exposure to titanium dioxide nanoparticles. J Hazard Mater. 2011;191(1–3):32–40.
12. Tsai MC, Chen YH, Chiang LY. Polyhydroxylated C60, fullerenol, a novel free-radical trapper, prevented hydrogen peroxide- and cumene hydroperoxide-elicited changes in rat hippocampus in-vitro. J Pharm Pharmacol. 1997;49(4):438–445.
13. Dugan LL, Lovett EG, Quick KL, Lotharius J, Lin TT, O’Malley KL. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord. 2001;7(3):243–246.
14. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49–60.
15. Jain S, Hirst DG, O’Sullivan JM. Gold nanoparticles as novel agents for cancer therapy. Br J Radiol. 2012;85(1010):101–113.
16. Boyce VS, Mendell LM. Neurotrophic factors in spinal cord injury. Handb Exp Pharmacol. 2014;220:443–460.
17. Williamson A, Singh S, Fernekorn U, Schober A. The future of the patient-specific Body-on-a-chip. Lab Chip. 2013;13(18):3471–3480.
18. Bokara KK, Kim JY, Lee YI, Yun K, Webster TJ, Lee JE. Biocompatability of carbon nanotubes with stem cells to treat CNS injuries. Anat Cell Biol. 2013;46(2):85–92.
19. Fabbro A, Cellot G, Prato M, Ballerini L. Interfacing neurons with carbon nanotubes: (re)engineering neuronal signaling. Prog Brain Res. 2011;194:241–252.
20. Ellis-Behnke RG, Liang YX, You SW, et al. Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci U S A. 2006;103(13): 5054–5059.
21. Yu QZ, Xu SL, Zhang KH, Shan YM. Multi-porous electroactive poly(L-lactic acid)/polypyrrole composite micro/nano fibrous scaffolds promote neurite outgrowth in PC12 cells. Neural Regen Res. 2013; 8(1):31–38.
22. Ekinci KL, Yakhot V, Rajauria S, Colosqui C, Karabacak DM. High-frequency nanofluidics: a universal formulation of the fluid dynamics of MEMS and NEMS. Lab Chip. 2010;10(22):3013–3025.
23. Lee SA, Vasquez DJ, Bergsneider M, Judy JW. Magnetic microactuators for MEMS-enabled ventricular catheters for hydrocephalus. Conf Proc IEEE Eng Med Biol Soc. 2006;1:2494–2497.
24. Wang H, Mararenko A, Cao GX, et al. Multifunctional 1D magnetic and fluorescent nanoparticle chains for enhanced MRI, fluorescent cell imaging, and combined photothermal/chemotherapy. ACS Appl Mater Interfaces. 2014;6(17):15309–15317.
25. Carvalho A, Martins MB, Corvo ML, Feio G. Enhanced contrast efficiency in MRI by PEGylated magnetoliposomes loaded with PEGylated SPION: effect of SPION coating and micro-environment. Mater Sci Eng C Mater Biol Appl. 2014;43:521–526.
26. Murgia S, Falchi AM, Mano M, et al. Nanoparticles from lipid-based liquid crystals: emulsifier influence on morphology and cytotoxicity. J Phys Chem B. 2010;114(10):3518–3525.
27. Stockhammer F, Misch M, Horn P, Koch A, Fonyuy N, Plotkin M. Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas. Acta Neurochir (Wien). 2009;151(11):1377–1383.
28. Geraets L, Oomen AG, Schroeter JD, Coleman VA, Cassee FR. Tissue distribution of inhaled micro- and nano-sized cerium oxide particles in rats: results from a 28-day exposure study. Toxicol Sci. 2012;127(2): 463–473.
29. Kozlovskaya L, Abou-Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release. 2014;189(10):133–140.
30. Shah L, Yadav S, Amiji M. Nanotechnology for CNS delivery of bio-therapeutic agents. Drug Deliv Transl Res. 2013;3(4):336–351.
31. Wolak DJ, Thorne RG. Diffusion of macromolecules in the brain: implications for drug delivery. Mol Pharm. 2013;10(5):1492–1504.
32. von Bohlen und Halbach O. Immunohistological markers for staging neurogenesis in adult hippocampus. Cell Tissue Res. 2007;329(3):409–420.
33. Hirst SM, Karakoti A, Singh S, et al. Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice. Environ Toxicol. 2013;28(2):107–118.
34. Tang JL, Xiong L, Wang S, et al. Distribution, translocation and accumulation of silver nanoparticles in rats. J Nanosci Nanotechnol. 2009;9(8):4924–4932.
35. Ma LL, Liu J, Li N, et al. Oxidative stress in the brain of mice caused by translocated nanoparticulate TiO2 delivered to the abdominal cavity. Biomaterials. 2010;31(1):99–105.
36. Wang JX, Zhou GQ, Chen CY, et al. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol Lett. 2007;168(2):176–185.
37. Boyes WK, Chen R, Chen CY, Yokel RA. The neurotoxic potential of engineered nanomaterials. Neurotoxicology. 2012;33(4):902–910.
38. Win-Shwe TT, Fujimaki H. Nanoparticles and neurotoxicity. Int J Mol Sci. 2011;12(9):6267–6280.
39. Mirsattari SM, Hammond RR, Sharpe MD, Leung FY, Young GB. Myoclonic status epilepticus following repeated oral ingestion of colloidal silver. Neurology. 2004;62(8):1408–1410.
40. Hu RP, Gong XL, Duan YM, et al. Neurotoxicological effects and the impairment of spatial recognition memory in mice caused by exposure to TiO2 nanoparticles. Biomaterials. 2010;31(31):8043–8050.
41. Siddiqui MA, Alhadlaq HA, Ahmad J, Al-Khedhairy AA, Musarrat J, Ahamed M. Copper oxide nanoparticles induced mitochondria mediated apoptosis in human hepatocarcinoma cells. PLoS One. 2013;8(8):e69534.
42. Hougaard KS, Jackson P, Jensen KA, et al. Effects of prenatal exposure to surface-coated nanosized titanium dioxide (UV-Titan). A study in mice. Part Fibre Toxicol. 2010;7:16.
43. Takeda K, Suzuki KI, Ishihara A, et al. Nanoparticles transferred from pregnant mice to their offspring can damage the genital and cranial nerve systems. J Health Sci. 2009;55(1):95–102.
44. Takahashi Y, Mizuo K, Shinkai Y, Oshio S, Takeda K. Prenatal exposure to titanium dioxide nanoparticles increases dopamine levels in the prefrontal cortex and neostriatum of mice. J Toxicol Sci. 2010; 35(5):749–756.
45. Shimizu M, Tainaka H, Oba T, Mizuo K, Umezawa M, Takeda K. Maternal exposure to nanoparticulate titanium dioxide during the prenatal period alters gene expression related to brain development in the mouse. Part Fibre Toxicol. 2009;6:20.
46. Gao X, Yin S, Tang M, et al. Effects of developmental exposure to TiO2 nanoparticles on synaptic plasticity in hippocampal dentate gyrus area: an in vivo study in anesthetized rats. Biol Trace Elem Res. 2011; 143(3):1616–1628.
47. Mohammadipour A, Fazel A, Haghir H, et al. Maternal exposure to titanium dioxide nanoparticles during pregnancy; impaired memory and decreased hippocampal cell proliferation in rat offspring. Environ Toxicol Pharmacol. 2014;37(2):617–625.
48. Asharani PV, Hande MP, Valiyaveettil S. Anti-proliferative activity of silver nanoparticles. BMC Cell Biol. 2009;10:65.
49. Xia T, Li N, Nel AE. Potential health impact of nanoparticles. Annu Rev Publ Health. 2009;30:137–150.
50. Rang FJ, Boonstra J. Causes and consequences of age-related changes in DNA methylation: a role for ROS? Biology. 2014;3(2):403–425.
51. Li J, O W, Li W, Jiang ZG, Ghanbari HA. Oxidative stress and neurodegenerative disorders. Int J Mol Sci. 2013;14(12):24438–24475.
52. Smith JA, Park S, Krause JS, Banik NL. Oxidative stress, DNA damage, and the telomeric complex as therapeutic targets in acute neurodegeneration. Neurochem Int. 2013;62(5):764–775.
53. Sorce S, Krause KH. NOX enzymes in the central nervous system: from signaling to disease. Antioxid Redox Signal. 2009;11(10):2481–2504.
54. Thomas MP, Chartrand K, Reynolds A, Vitvitsky V, Banerjee R, GendelmanHE. Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson’s disease. J Neurochem. 2007;100(2):503–519.
55. Schappi MG, Jaquet V, Belli DC, Krause KH. Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase. Semin Immunopathol. 2008;30(3):255–271.
56. Massaad CA, Klann E. Reactive oxygen species in the regulation of synaptic plasticity and memory. Antioxid Redox Signal. 2011;14(10):2013–2054.
57. Brieger K, Schiavone S, Miller FJ, Krause KH. Reactive oxygen species: from health to disease. Swiss Med Wkly. 2012;142:w13659.
58. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311(5761):622–627.
59. Hanley C, Thurber A, Hanna C, Punnoose A, Zhang JH, Wingett DG. The influences of cell type and ZnO nanoparticle size on immune cell cytotoxicity and cytokine induction. Nanoscale Res Lett. 2009;4(12): 1409–1420.
60. Luo YH, Wu SB, Wei YH, et al. Cadmium-based quantum dot induced autophagy formation for cell survival via oxidative stress. Chem Res Toxicol. 2013;26(5):662–673.
61. Yu KN, Yoon TJ, Minai-Tehrani A, et al. Zinc oxide nanoparticle induced autophagic cell death and mitochondrial damage via reactive oxygen species generation. Toxicol In Vitro. 2013;27(4):1187–1195.
62. Lee J, Giordano S, Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J. 2012;441(2): 523–540.
63. Tobe EH. Mitochondrial dysfunction, oxidative stress, and major depressive disorder. Neuropsychiatr Dis Treat. 2013;9:567–573.
64. Marazziti D, Baroni S, Picchetti M, et al. Psychiatric disorders and mitochondrial dysfunctions. Eur Rev Med Pharmacol. 2012;16(2):270–275.
65. Long TC, Saleh N, Tilton RD, Lowry GV, Veronesi B. Titanium dioxide (P25) produces reactive oxygen species in immortalized brain microglia (BV2): implications for nanoparticle neurotoxicity. Environ Sci Technol. 2006;40(14):4346–4352.
66. Freyre-Fonseca V, Delgado-Buenrostro NL, Gutierrez-Cirlos EB, etal. Titanium dioxide nanoparticles impair lung mitochondrial function. Toxicol Lett. 2011;202(2):111–119.
67. Huerta-Garcia E, Perez-Arizti JA, Marquez-Ramirez SG, et al. Titanium dioxide nanoparticles induce strong oxidative stress and mitochondrial damage in glial cells. Free Radical Biol Med. 2014;73:84–94.
68. Zanotto A, Braganhol E, Battastini AM, Moreira JC. Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFκB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling. Invest New Drugs. 2012;30(6):2252–2262.
69. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120(4):483–495.
70. Hardas SS, Butterfield DA, Sultana R, et al. Brain distribution and toxicological evaluation of a systemically delivered engineered nanoscale ceria. Toxicol Sci. 2010;116(2):562–576.
71. Hardas SS, Sultana R, Warrier G, et al. Rat hippocampal responses up to 90 days after a single nanoceria dose extends a hierarchical oxidative stress model for nanoparticle toxicity. Nanotoxicology. 2014;8: 155–166.
72. Awasthi KK, John PJ, Awasthi A, Awasthi K. Multi walled carbon nano tubes induced hepatotoxicity in Swiss albino mice. Micron. 2013;44:359–364.
73. Gomes T, Pereira CG, Cardoso C, Pinheiro JP, Cancio I, Bebianno MJ. Accumulation and toxicity of copper oxide nanoparticles in the digestive gland of Mytilus galloprovincialis. Aquat Toxicol. 2012;118:72–79.
74. Li HC, Zhou QF, Wu Y, Fu JJ, Wang T, Jiang GB. Effects of waterborne nano-iron on medaka (Oryzias latipes): antioxidant enzymatic activity, lipid peroxidation and histopathology. Ecotoxicol Environ Safe. 2009;72(3):684–692.
75. Krause KH. Aging: a revisited theory based on free radicals generated by NOX family NADPH oxidases. Exp Gerontol. 2007;42(4):256–262.
76. Wilhelmi V, Fischer U, Weighardt H, et al. Zinc oxide nanoparticles induce necrosis and apoptosis in macrophages in a p47phox-and Nrf2-independent manner. PLoS One. 2013;8(6):e65704.
77. Culcasi M, Benameur L, Mercier A, et al. EPR spin trapping evaluation of ROS production in human fibroblasts exposed to cerium oxide nanoparticles: evidence for NADPH oxidase and mitochondrial stimulation. Chem Biol Interact. 2012;199(3):161–176.
78. Soenen SJ, Rivera-Gil P, Montenegro JM, Parak WJ, De Smedt SC, Braeckmans K. Cellular toxicity of inorganic nanoparticles: common aspects and guidelines for improved nanotoxicity evaluation. Nano Today. 2011;6(5):446–465.
79. Jeong SH, Kim HJ, Ryu HJ, et al. ZnO nanoparticles induce TNF-α expression via ROS-ERK-Egr-1 pathway in human keratinocytes. J Dermatol Sci. 2013;72(3):263–273.
80. Wang J, Deng X, Zhang F, Chen D, Ding W. ZnO nanoparticle-induced oxidative stress triggers apoptosis by activating JNK signaling pathway in cultured primary astrocytes. Nanoscale Res Lett. 2014;9(1):117.
81. Marano F, Hussain S, Rodrigues-Lima F, Baeza-Squiban A, Boland S. Nanoparticles: molecular targets and cell signalling. Arch Toxicol. 2011;85(7):733–741.
82. Nel AE, Madler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8(7):543–557.
83. Mudunkotuwa IA, Grassian VH. Histidine adsorption on TiO2 nanoparticles: an integrated spectroscopic, thermodynamic, and molecular-based approach toward understanding nano-bio interactions. Langmuir. 2014;30(29):8751–8760.
84. Wang ZY, von dem Bussche A, Kabadi PK, Kane AB, Hurt RH. Biological and environmental transformations of copper-based nanomaterials. ACS Nano. 2013;7(10):8715–8727.
85. Domenech M, Marrero-Berrios I, Torres-Lugo M, Rinaldi C. Lysosomal membrane permeabilization by targeted magnetic nanoparticles in alternating magnetic fields. ACS Nano. 2013;7(6):5091–5101.
86. Yang M, Zhang M, Tahara Y, et al. Lysosomal membrane permeabilization: carbon nanohorn-induced reactive oxygen species generation and toxicity by this neglected mechanism. Toxicol Appl Pharmacol. 2014;280(1):117–126.
87. Li W, Zhao LN, Wei TT, Zhao YL, Chen CY. The inhibition of death receptor mediated apoptosis through lysosome stabilization following internalization of carboxyfullerene nanoparticles. Biomaterials. 2011;32(16):4030–4041.
88. Nouri-Nigjeh E, Permentier HP, Bischoff R, Bruins AP. Lidocaine oxidation by electrogenerated reactive oxygen species in the light of oxidative drug metabolism. Anal Chem. 2010;82(18):7625–7633.
89. Naqvi S, Samim M, Abdin MZ, et al. Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int J Nanomedicine. 2010;5:983–989.
90. Park EJ, Choi J, Park YK, Park K. Oxidative stress induced by cerium oxide nanoparticles in cultured BEAS-2B cells. Toxicology. 2008; 245(1–2):90–100.
91. Kim IS, Baek M, Choi SJ. Comparative cytotoxicity of Al2O3, CeO2, TiO2 and ZnO nanoparticles to human lung cells. J Nanosci Nanotechnol. 2010;10(5):3453–3458.
92. Manke A, Wang LY, Rojanasakul Y. Mechanisms of nanoparticle-induced oxidative stress and toxicity. Biomed Res Int. 2013;2013:942916.
93. Wu YN, Chen DH, Shi XY, et al. Cancer-cell-specific cytotoxicity of non-oxidized iron elements in iron core-gold shell NPs. Nanomed Nanotechnol. 2011;7(4):420–427.
94. Block ML, Elder A, Auten RL, et al. The outdoor air pollution and brain health workshop. Neurotoxicology. 2012;33(5):972–984.
95. Choi J, Zheng QD, Katz HE, Guilarte TR. Silica-based nanoparticle uptake and cellular response by primary microglia. Environ Health Perspect. 2010;118(5):589–595.
96. Gualtieri M, Capasso L, D’Anna A, Camatini M. Organic nanoparticles from different fuel blends: in vitro toxicity and inflammatory potential. J Appl Toxicol. 2014;34(11):1247–1255.
97. Xue Y, Wu J, Sun J. Four types of inorganic nanoparticles stimulate the inflammatory reaction in brain microglia and damage neurons in vitro. Toxicol Lett. 2012;214(2):91–98.
98. Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19(8):983–997.
99. Cheung ZH, Ip NY. Autophagy deregulation in neurodegenerative diseases – recent advances and future perspectives. J Neurochem. 2011;118(3):317–325.
100. Podila R, Brown JM. Toxicity of engineered nanomaterials: a physicochemical perspective. J Biochem Mol Toxicol. 2013;27(1):50–55.
101. Zhang Y, Yu CG, Huang GY, Wang CL, Wen LP. Nano rare-earth oxides induced size-dependent vacuolization: an independent pathway from autophagy. Int J Nanomedicine. 2010;5:601–609.
102. Kenzaoui BH, Bernasconi CC, Guney-Ayra S, Juillerat-Jeanneret L. Induction of oxidative stress, lysosome activation and autophagy by nanoparticles in human brain-derived endothelial cells. Biochem J. 2012;441:813–821.
103. Roy R, Singh SK, Chauhan KS, Das M, Tripathi A, Dwivedi PD. Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition. Toxicol Lett. 2014;227(1):29–40.
104. Scherz-Shouval R, Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends Biochem Sci. 2011;36(1):30–38.
105. Shi CS, Shenderov K, Huang NN, et al. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol. 2012;13(3): 255–263.
106. Wang F, Bexiga MG, Anguissola S, et al. Time resolved study of cell death mechanisms induced by amine-modified polystyrene nanoparticles. Nanoscale. 2013;5(22):10868–10876.
107. Stern ST, Adiseshaiah PP, Crist RM. Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. Part Fibre Toxicol. 2012;9:20.
108. Neibert KD, Maysinger D. Mechanisms of cellular adaptation to quantum dots – the role of glutathione and transcription factor EB. Nanotoxicology. 2012;6(3):249–262.
109. Polito VA, Li HM, Martini-Stoica H, et al. Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB. EMBO Mol Med. 2014;6(9):1142–1160.
110. Loos B, Engelbrecht AM, Lockshin RA, Klionsky DJ, Zakeri Z. The variability of autophagy and cell death susceptibility unanswered questions. Autophagy. 2013;9(9):1270–1285.
111. Loos B, Engelbrecht AM. Cell death: a dynamic response concept. Autophagy. 2009;5(5):590–603.
112. Marquez-Ramirez SG, Delgado-Buenrostro NL, Chirino YI, IglesiasGG, Lopez-Marure R. Titanium dioxide nanoparticles inhibit proliferation and induce morphological changes and apoptosis in glial cells. Toxicology. 2012;302(2–3):146–156.
113. Lai JC, Lai MB, Jandhyam S, et al. Exposure to titanium dioxide and other metallic oxide nanoparticles induces cytotoxicity on human neural cells and fibroblasts. Int J Nanomedicine. 2008;3(4):533–545.
114. Liu SC, Xu LJ, Zhang T, Ren GG, Yang Z. Oxidative stress and apoptosis induced by nanosized titanium dioxide in PC12 cells. Toxicology. 2010;267(1–3):172–177.
115. Long TC, Tajuba J, Sama P, et al. Nanosize titanium dioxide stimulates reactive oxygen species in brain microglia and damages neurons in vitro. Environ Health Perspect. 2007;115(11):1631–1637.
116. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small. 2010;6(1):12–21.
117. Ze Y, Zheng L, Zhao X, et al. Molecular mechanism of titanium dioxide nanoparticles-induced oxidative injury in the brain of mice. Chemosphere. 2013;92(9):1183–1189.
118. Yokel RA, MacPhail RC. Engineered nanomaterials: exposures, hazards, and risk prevention. J Occup Med Toxicol. 2011;6:7.
119. Kumar V, Kumari A, Guleria P, Yadav SK. Evaluating the toxicity of selected types of nanochemicals. Rev Environ Contam Toxicol. 2012;215:39–121.
120. Kim TH, Kim M, Park HS, Shin US, Gong MS, Kim HW. Size-dependent cellular toxicity of silver nanoparticles. J Biomed Mater Res A. 2012;100A(4):1033–1043.
121. Sharma A, Muresanu DF, Patnaik R, Sharma HS. Size- and age-dependent neurotoxicity of engineered metal nanoparticles in rats. Mol Neurobiol. 2013;48(2):386–396.
122. Gratton SE, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008;105(33):11613–11618.
123. Meng H, Yang S, Li ZX, et al. Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism. ACS Nano. 2011;5(6):4434–4447.
124. Xu ZL, Liu CS, Wei J, Sun J. Effects of four types of hydroxyapatite nanoparticles with different nanocrystal morphologies and sizes on apoptosis in rat osteoblasts. J Appl Toxicol. 2012;32(6):429–435.
125. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm. 2008;5(2):316–327.
126. Huang XL, Teng X, Chen D, Tang FQ, He JQ. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials. 2010;31(3):438–448.
127. Asefa T, Tao ZM. Biocompatibility of mesoporous silica nanoparticles. Chem Res Toxicol. 2012;25(11):2265–2284.
128. Thorek DL, Tsourkas A. Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials. 2008;29(26):3583–3590.
129. Arvizo RR, Miranda OR, Thompson MA, et al. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett. 2010;10(7):2543–2548.
130. Tarn D, Ashley CE, Xue M, Carnes EC, Zink JI, Brinker CJ. Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. Acc Chem Res. 2013;46(3):792–801.
131. Lin JQ, Zhang HW, Chen Z, Zheng YG. Penetration of lipid membranes by gold nanoparticles: insights into cellular uptake, cytotoxicity, and their relationship. ACS Nano. 2010;4(9):5421–5429.
132. Templeton AC, Wuelfing WP, Murray RW. Monolayer-protected cluster molecules. Acc Chem Res. 2000;33(1):27–36.
133. Lao F, Chen L, Li W, et al. Fullerene nanoparticles selectively enter oxidation-damaged cerebral microvessel endothelial cells and inhibit JNK-related apoptosis. ACS Nano. 2009;3(11):3358–3368.
134. Zhao F, Zhao Y, Liu Y, Chang XL, Chen CY, Zhao YL. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small. 2011; 7(10):1322–1337.
135. Wang JX, Liu Y, Jiao F, et al. Time-dependent translocation and potential impairment on central nervous system by intranasally instilled TiO2 nanoparticles. Toxicology. 2008;254(1–2):82–90.
136. Wang JX, Chen CY, Liu Y, et al. Potential neurological lesion after nasal instillation of TiO2 nanoparticles in the anatase and rutile crystal phases. Toxicol Lett. 2008;183(1–3):72–80.
137. Zhang LL, Bai R, Li B, et al. Rutile TiO2 particles exert size and surface coating dependent retention and lesions on the murine brain. Toxicol Lett. 2011;207(1):73–81.
138. Sousa F, Mandal S, Garrovo C, et al. Functionalized gold nanoparticles: a detailed in vivo multimodal microscopic brain distribution study. Nanoscale. 2010;2(12):2826–2834.
139. Albanese A, Walkey CD, Olsen JB, Guo HB, Emili A, Chan WC. Secreted biomolecules alter the biological identity and cellular interactions of nanoparticles. ACS Nano. 2014;8(6):5515–5526.
140. Sadhukha T, Wiedmann TS, Panyam J. Enhancing therapeutic efficacy through designed aggregation of nanoparticles. Biomaterials. 2014; 35(27):7860–7869.
141. Sur I, Altunbek M, Kahraman M, Culha M. The influence of the surface chemistry of silver nanoparticles on cell death. Nanotechnology. 2012;23(37):375102.
142. Mudunkotuwa IA, Grassian VH. The devil is in the details (or the surface): impact of surface structure and surface energetics on understanding the behavior of nanomaterials in the environment. J Environ Monit. 2011;13(5):1135–1144.
143. Bell IR, Ives JA, Jonas WB. Nonlinear effects of nanoparticles: biological variability from hormetic doses, small particle sizes, and dynamic adaptive interactions. Dose Response. 2014;12(2):202–232.
144. Kroll A, Dierker C, Rommel C, et al. Cytotoxicity screening of 23 engineered nanomaterials using a test matrix of ten cell lines and three different assays. Part Fibre Toxicol. 2011;8:9.
145. Kim JS, Peters TM, O’Shaughnessy PT, Adamcakova-Dodd A, Thorne PS. Validation of an in vitro exposure system for toxicity assessment of air-delivered nanomaterials. Toxicol In Vitro. 2013;27(1):164–173.
146. Adamcakova-Dodd A, Stebounova LV, Kim JS, et al. Toxicity assessment of zinc oxide nanoparticles using sub-acute and sub-chronic murine inhalation models. Part Fibre Toxicol. 2014;11:15.
147. Yokel R, Grulke E, MacPhail R. Metal-based nanoparticle interactions with the nervous system: the challenge of brain entry and the risk of retention in the organism. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5(4):346–373.
148. Ji QM, Guo CY, Yu XY, et al. Flake-shell capsules: adjustable inorganic structures. Small. 2012;8(15):2345–2349.
149. Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med. 2013;19(7):428–446.
150. Lyon DY, Adams LK, Falkner JC, Alvarezt PJ. Antibacterial activity of fullerene water suspensions: effects of preparation method and particle size. Environ Sci Technol. 2006;40(14):4360–4366.
151. Marchesan S, Da Ros T, Spalluto G, Balzarini J, Prato M. Anti-HIV properties of cationic fullerene derivatives. Bioorg Med Chem Lett. 2005;15(15):3615–3618.
152. Ma HL, Liang XJ. Fullerenes as unique nanopharmaceuticals for disease treatment. Sci China Chem. 2010;53(11):2233–2340.
153. Meng H, Xing GM, Blanco E, et al. Gadolinium metallofullerenol nanoparticles inhibit cancer metastasis through matrix metalloproteinase inhibition: imprisoning instead of poisoning cancer cells. Nanomedicine. 2012;8(2):136–146.
154. Jin H, Chen WQ, Tang XW, et al. Polyhydroxylated C(60), fullerenols, as glutamate receptor antagonists and neuroprotective agents. J Neurosci Res. 2000;62(4):600–607.
155. Huang SS, Tsai SK, Chih CL, et al. Neuroprotective effect of hexasulfobutylated C60 on rats subjected to focal cerebral ischemia. Free Radic Biol Med. 2001;30(6):643–649.
156. Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev. 2014;71:2–14.
157. Tosi G, Bortot B, Ruozi B, et al. Potential use of polymeric nanoparticles for drug delivery across the blood–brain barrier. Curr Med Chem. 2013;20(17):2212–2225.
158. Kulkarni SA, Feng SS. Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res. 2013;30(10):2512–2522.
159. Gref R, Luck M, Quellec P, et al. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3–4):301–313.
160. Zhang Y, Boado RJ, Pardridge WM. Marked enhancement in gene expression by targeting the human insulin receptor. J Gene Med. 2003;5(2):157–163.
161. Chang J, Jallouli Y, Kroubi M, et al. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood–brain barrier. Int J Pharma. 2009;379(2):285–292.
162. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res. 1999;16(10):1564–1569.
163. Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res. 1999;16(12):1836–1842.
164. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood–brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res. 1997;14(3):325–328.
165. Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ, Allen DD. Brain uptake of thiamine-coated nanoparticles. J Control Release. 2003;93(3):271–282.
166. Salman HH, Gamazo C, Agueros M, Irache JM. Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles. Vaccine. 2007;25(48):8123–8132.
167. Oyewumi MO, Liu SQ, Moscow JA, Mumper RJ. Specific association of thiamine-coated gadolinium nanoparticles with human breast cancer cells expressing thiamine transporters. Bioconjugate Chem. 2003;14(2):404–411.
168. Grover A, Hirani A, Pathak Y, Sutariya V. Brain-targeted delivery of docetaxel by glutathione-coated nanoparticles for brain cancer. AAPS Pharm Sci Tech. 2014;15(6):1562–1568.
169. Wei X, Zhan C, Chen X, Hou J, Xie C, Lu W. Retro-inverso isomer of angiopep-2: a stable d-peptide ligand inspires brain-targeted drug delivery. Mol Pharm. 2014;11(10):3261–3268.
170. Ying X, Wang Y, Liang J, et al. Angiopep-conjugated electro-responsive hydrogel nanoparticles: therapeutic potential for epilepsy. Angew Chem Int Ed Engl. 2014;53(46):12436–12440.
171. Dreis S, Rothweller F, Michaelis A, Cinatl J, Kreuter J, Langer K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm. 2007;341(1–2):207–214.
172. Damascelli B, Cantu G, Mattavelli F, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007) – phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer. 2001;92(10):2592–2602.
173. Dadparvar M, Wagner S, Wien S, et al. HI 6 human serum albumin nanoparticles – development and transport over an in vitro blood–brain barrier model. Toxicol Lett. 2011;206(1):60–66.
174. Chassepot A, Ball V. Human serum albumin and other proteins as templating agents for the synthesis of nanosized dopamine-eumelanin. J Colloid Interf Sci. 2014;414:97–102.